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Abstract
Background: Children commonly present to Emergency Departments (ED) with a non-blanching rash in the context
of a feverish illness. While most have a self-limiting viral illness, this combination of features potentially represents
invasive serious bacterial infection, including meningococcal septicaemia. A paucity of definitive diagnostic testing creates
diagnostic uncertainty for clinicians; a safe approach mandates children without invasive disease are often admitted and
treated with broad-spectrum antibiotics. Conversely, a cohort of children still experience significant mortality and
morbidity due to late diagnosis. Current management is based on evidence which predates (i) the introduction
of meningococcal B and C vaccines and (ii) availability of point of care testing (POCT) for procalcitonin (PCT) and
Neisseria meningitidis DNA.
Methods: This PiC study is a prospective diagnostic accuracy study evaluating (i) rapid POCT for PCT and N. meningitidis
DNA and (ii) performance of existing clinical practice guidelines (CPG) for feverish children with non-blanching rash. All
children presenting to the ED with a history of fever and non-blanching rash are eligible. Children are managed as normal,
with detailed prospective collection of data pertinent to CPGs, and a throat swab and blood used for rapid POCT. The
study is running over 2 years and aims to recruit 300 children.
Primary objective:
 Report on the diagnostic accuracy of POCT for (i) N. meningitidis DNA and (ii) PCT in the diagnosis of early MD
 Report on the diagnostic accuracy of POCT for PCT in the diagnosis of Invasive bacterial infection
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Secondary objectives:
 Evaluate the performance accuracy of existing CPGs
 Evaluate cost-effectiveness of available diagnostic testing strategies
 Explore views of (i) families and (ii) clinicians on research without prior consent using qualitative methodology
 Report on the aetiology of NBRs in children with a feverish illness
Discussion: The PiC study will provide important information for policy makers regarding the value of POCT and on the
utility and cost of emerging diagnostic strategies. The study will also identify which elements of existing CPGs may merit
inclusion in any future study to derive clinical decision rules for this population.
Trial registration: NCT03378258. Retrospectively registered on December 19, 2017.
Keywords: Meningococcal, Meningitis, Sepsis, Management, Loop-mediated-isothermal AMPlification, Procalcitonin
Background
Early diagnosis of meningococcal disease (MD) is associated
with improved outcomes including reduced morbidity and
mortality [1, 2]. However during its prodrome phase inva-
sive MD, which most often presents with a fever and
non-blanching rash (NBR), is indistinguishable from many
self-limiting viral infections, creating a significant diagnostic
challenge for clinicians. This combination of features is a
common presentation to Emergency Departments (ED) and
inevitably leads to caution amongst clinicians, resulting in
admission and administration of broad spectrum antibiotics
to large numbers of children who do not have MD. Despite
this cautious approach a cohort of children are still diag-
nosed late [1, 3]. Paediatric Emergency Research in the UK
and Ireland (PERUKI, a research collaborative) highlighted
these challenges in the context of a paucity of relevant evi-
dence, and identified the derivation of a clinical decision rule
(CDR) for the management of feverish children with NBRs
as a priority for future research [4, 5].
Current UK guidance
There are currently two clinical practice guidelines
(CPG) in widespread use in the UK for the management
of children with NBR. These are:
 National Institute for Health and Care Excellence
(NICE) CG102 “Meningitis (bacterial) and
meningococcal septicaemia in under 16s:
recognition, diagnosis and management”
 The Newcastle-Birmingham-Liverpool algorithm [3, 6].
These CPGs were developed based on data collected
prior to the introduction of Meningococcal vaccines into
the UK vaccination schedule (Table 1) [6–9]. Both CPGs
advocate a similar and cautious approach to manage-
ment of non-blanching rashes in children. Both CPGs
are reported to be highly sensitive for the diagnosis of
MD (NICE 97%) and (NBL) 100% [6]. The specificity of
the two CPGs has been estimated as 50% (NICE) 82%
(NBL) [6]. The most significant difference between the
two CPGs is that in the NBL CPG does not include fever
or history of fever whereas the NICE CPG requires a
fever (or history of fever) and NBR [6]. Data on sensitiv-
ity and specificity of the existing CPGs was collected
largely before the introduction of meningococcal B and
C vaccination meaning their performance in the current
post vaccination era is unknown.
Point of care testing
Current guidance suggests a range of investigations
aimed at establishing the risk of invasive disease, and/or
identifying a pathogen. To date, these have predomin-
antly been performed in laboratory settings. However re-
cent advances in technology have created the potential
for point of care testing to be employed, either to iden-
tify MD, or to stratify risk of invasive disease. The two
which offer most promise in the context of NBR are
Loop Mediated Isothermal Amplification for Meningo-
coccal DNA (LAMP MD) and procalcitonin (PCT).
Lamp md
LAMP-MD is a rapid molecular amplification test for the
detection of all serogroups of N. meningitidis DNA. It can
be performed in the ED on a bench top analyser and pro-
vides results within 30 min (Fig. 1). Initial testing has
shown that LAMP-MD has superior sensitivity (0.89
[95%CI 0.72–0.96]) and specificity (1.0 [95%CI 0.97–1.0])
in diagnosing MD than traditional tests (C-reactive pro-
tein [CRP] and White Blood Cell counts [WBC]) recom-
mended by NICE [10, 11]. The LAMP-MD test is now
available commercially and is CE-IVD approved. The test
performs equally well on blood samples and throat swabs,
[10] with results available more quickly from throat swabs
due to a shorter and simpler DNA extraction process.
Procalcitonin
Procalcitonin (PCT) is the precursor for calcitonin and
is produced by parafollicular cells. It is a 116-amino acid
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protein that has roles in calcium metabolism. PCT is el-
evated during infection and typically rises within 2 h of
the onset of a bacterial infection. A recently published
meta-analysis of 6 studies, including 881 children, found
PCT to be more sensitive (0.89 [95%CI 0.76–0.96]) and
specific (0.74 [95%CI 0.4–0.92]) in diagnosing early MD
than CRP or WBC [12]. A further strength of PCT is
that it rises within 2 h of onset of bacterial illness and
peaks at around 6 h (much earlier than CRP) [12]. ED
clinical staff can perform PCT POCT on a bench top
analyser with results available within 20 min. (Fig. 2)
Methods/design
As a diagnostic accuracy study our Petechiae in Children
(PiC) study adheres to the STARD criteria for the
reporting of diagnostic accuracy studies [13]. The gold
standard test against which our outcomes are measured
is quantitative PCR (qPCR) for N. meningitidis DNA in
a sterile body site (blood or CSF). Or confirmation of an
invasive bacterial infection through positive culture or
qPCR of a bacterial pathogen.
Study registration
The PiC study was registered at https://www.clinicaltrials
.gov (trial registration: NCT03378258) on the 19th of
December 2017. At the time of registration 24 patients
had been recruited to the PiC study which opened on the
22nd of November 2017.
Objectives
The co-primary outcomes are the diagnostic accuracy
(sensitivity, specificity, positive predictive value, and nega-
tive predictive value) of:
 POCT for (i) N. meningitidis DNA and (ii) PCT
in the diagnosis of MD in children with fever and
NBR
 POCT for PCT in the diagnosis of Invasive bacterial
infection
Secondary objectives:
 Evaluate the performance accuracy of existing CPGs
in identifying MD
 Evaluate cost-effectiveness of available diagnostic
testing strategies
 Explore views of (i) families and (ii) clinicians on
research without prior consent (RWPC) using
qualitative methodology
Fig. 1 Hibergene LAMP-MD testing equipment
Fig. 2 Samsung IB10 (BRAHMS) Procalcitonin
Table 1 Current UK vaccination against invasive meningococcal
disease
Current UK Vaccination Against Invasive Meningococcal Disease
Vaccine (Serogroups) Year Introduced
into schedule
Age given
B 2015 8 weeks, 16 weeks, 1 year
C 1999 1 yeara
ACWY 2015 14 years, University
students 19–25 years
aPrior to 2016 meningococcal C vaccine was also administered at 12 weeks
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 Report on the aetiology of NBRs in children with a
feverish illness
Study population and setting
Inclusion criteria
 All children < 14 years of age attending the ED with
reported or recorded fever (≥38 °C) and NBR.
 Unwell appearing children with features of
meningococcal sepsis/meningitis as outlined in the
National Institute for Health and Care Excellence
(NICE) CG102 “Meningitis (bacterial) and
meningococcal septicaemia in under 16s:
recognition, diagnosis and management” [3].
Exclusion criteria
1. Children with pre-existing haematological
conditions such as haematological malignancy,
idiopathic thrombocytopenic purpura (ITP) and
coagulopathy will be excluded.
2. Existing Henoch-Schonlein purpura (HSP) under
follow up
Sample size justification
We have calculated that we need 203 test negative pa-
tients (negative LAMP & low procalcitonin) to estimate
a negative predictive value (NPV) of 95% or greater with
confidence intervals of +/− 3% (Calculation below). Dis-
ease prevalence is estimated at 15% or lower, based on
preparatory work in our centre and other epidemiologic
studies, and we anticipate a combined refusal of consent
and dropout rate of 10%. We therefore aim to recruit a
total of 300 patients to achieve this. We have chosen to
focus on NPV because with possible MD the emphasis
is on exclusion of a life-threatening infection and as such
and test or CPG must have a high NPV.
NPV Calculation
Nnegative = Z0.025
2x (NPV(1 ‐NPV))/W2 = 1.962x (0.95(1 ‐
0.95))/0.032 = 203
Assessments and procedures
The required assessments and procedures are outlined
in Table 2. Eligible children undergo POCT in parallel to
their standard ED care with no delay (Fig. 3). Residual
specimens beyond what is needed for standard care is
tested using the Hibergene LAMP-MD and the Samsung
IB10 (BRAHMS) PCT.
Performing index tests - blood samples & throat swabs
POCT is performed by ED clinical staff, with bespoke
training provided by the research team, and a training
log maintained. Members of the research team are con-
tactable to provide support as required. Index tests are
performed as soon as possible, and are done prior to re-
sult of the reference standard test (Quantitative PCR)
being available.
LAMP-MD
A throat swab taken as part of routine care is mixed in a
sample buffer; a small aliquot of this (50 μl) is used, and
the main sample is forwarded to the laboratory as per
normal practice. Standard testing includes molecular
testing for N. meningitidis, human enteroviruses, and a
series of other viral targets using reference-laboratory
real-time PCR methods. The aliquot drawn in the ED is
analysed using the Hibergene LAMP-MD POCT test (giv-
ing positive/valid, negative/valid or invalid result) – Fig. 1.
Procalcitonin
0.5 ml of blood is taken from the samples collected as part
of routine care. POCT PCT testing is done on this sample
in the ED using the Samsung IB-10 analyser with a positive
threshold level of > 1.93 ng/ml. If insufficient blood is ob-
tained, then routine testing is prioritised. Routine blood
testing includes WBC, CRP, coagulation screen, blood gas,
and molecular testing for N. meningitidis, human enterovi-
ruses, and other viral and bacterial targets (including
Streptococcus pneumoniae and Haemophilus influenzae)
using reference-laboratory real-time PCR methods – Fig. 2.
Reference standards
In all cases of possible MD, blood and/or CSF is tested
for N. meningitidis DNA using quantitative crtA Taq-
Man PCR using standard UK laboratory methods. The
reference standard test is performed by staff blinded to
the result of the index test. A positive reference standard
test will be used to give a diagnosis of “confirmed MD”.
In cases where the diagnosis is unclear or where the
child has been diagnosed as “probable MD” by the clinical
team but where the reference standard test is negative a
committee of clinicians will review the anonymised med-
ical records blinded to results of POCT and decide if the
case can be given the diagnosis of “probable MD”.
For other invasive bacterial infections, the reference
standard test is positive culture or qPCR of bacterial
pathogen from a sterile body site (blood/CSF) performed
by staff blinded to the result of the index test.
Case report form (CRF)
All children recruited to the study will have a standardised
CRF completed by a member of the research team. Regu-
lar meetings will be arranged to ensure standardisation of
data collection. Demographic data will be collected as will
data pertinent to current CPGs. This includes, but is not
limited to, vital signs, overall wellness, duration of illness,
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Table 2 PiC Study assessments
In
ED
Follow-up
4 h 0–24 h Within 1 Month
Consent discussion X X X
Assessment of eligibility criteria X
POCT X
Laboratory assessments – routine bloods and throat swabs X
Notes review and CRF completion by member of research team X
Review of medical history by member of research team X
Qualitative interview conducted by TW X
Fig. 3 Flow diagram for study proceduress
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appearance and distribution of the rash, any spread of the
rash over time (including the first 4 h in hospital). Data
will be collected on investigations performed, treatments
given, final diagnosis, length of stay and survival to dis-
charge. Where data is unclear from the clinical record the
researcher will collect additional information from the
child’s parent and attending physician.
Interviews with parents and clinicians
The study includes interviews with (n = ~ 20) parents
and (n = ~ 5–10) clinicians involved with recruitment
and consent processes to explore their views on RWPC
in this study.
During the consent process, parents are asked whether
they consent to a qualitative telephone interview, which
takes place within one month of their child’s discharge
from hospital. All parents are invited to consent for a
qualitative interview, including those who decline the
use of their child’s information in the study. Interviews
will be conducted until data saturation is reached [14].
All interviews with parents and clinicians will be con-
ducted by TW. Any distress during the interviews will be
managed with care and compassion and participants will
be free to decline to answer any questions that they do
not wish to answer or to stop the interviews at any point.
Consent for audio recording will be sought. If consent is
not provided then the interview will not continue.
Research without prior consent (deferred consent)
Informed consent is a process initiated prior to an indi-
vidual agreeing to participate in a study and continues
throughout the individual’s participation. When consent
is deferred, an individual is agreeing to the use of data
that had already been collected for study purposes and
for continued participation in the study [15, 16]. Re-
search without prior consent in children has been shown
to be appropriate and well accepted by parents when
conducted in emergency situations and when informa-
tion and opportunities for consent are offered at an ap-
propriate time [15, 16]. In the PiC study we intend to
assess the performance of rapid bedside tests in the diag-
nosis of a life-threatening emergency. In this situation,
every minute counts and it is therefore not possible or
appropriate to delay testing whilst consent is obtained
(even for a few minutes). Following testing parents will
be approached at the earliest appropriate opportunity
and ideally within 24 h.
Approaching parents
A member of the research team will be notified of the par-
ticipation of the child in the study and will approach the
parent to seek consent as soon as possible after undergo-
ing POCT (ideally within 24 h). In the majority of cases
this will take place on a ward or in the ED. Consent will
only be sought once the child is stable and following con-
sultation with the clinical team caring for the child in line
with best practice recommendations [15–17].
Approaching parents in the ED
Not all children with a fever and NBR are admitted. If
the child appears well the clinician may choose to per-
form investigations and observe the child in the ED. Fol-
lowing a period of observation (typically 4–6 h) the child
may be discharged if they appear well and testing is re-
assuring. In this group, we intend to seek consent prior
to discharge. Before approaching the family in the ED,
the researcher checks with clinical staff that the child is
stable and timing is appropriate. An ED clinician ex-
plains the nature of the study to the parent and invites
them to discuss the study with the researcher.
Some children will be discharged before consent can
be obtained. In this instance, an ED clinician will contact
the parent by telephone (maximum of 3 attempts) to ex-
plain the study and invite parents to discuss the study
with a researcher, who then explains the reasons for
RWPC, and how to opt in or out of the study. The par-
ent is sent a patient information sheet (PIS), consent
form and follow up letter. This letter explains the study,
reasons for RWPC, how to opt in or out of the study,
and provide contact details for the research team. If after
4 weeks there is no response, a follow up letter, PIS, and
consent form are sent to the family. This explains the
study, reasons for RWPC, how to opt in or out, and pro-
vides contact details for the research team. This letter
also confirms that if no consent form is received within
4 weeks then the participant’s data will not be included
in the study.
Approaching parents on the wards
The research team is notified of enrolment and ap-
proaches the parent to seek consent as soon as possible
after undergoing POCT (ideally within 24 h). Based on
CONNECT best practice guidance for performing
RWPC the researcher checks with the clinical team that
the participant is stable and that timing is appropriate
before approaching the parent on the ward [16]. If the
participant’s condition has not stabilized additional time
will be allowed [16]. A member of the ward team ex-
plains the nature of the study and invites the parent to
talk with the researcher.
Death prior to consent being sought
This will be rare, but almost certainly will occur. When
a participant dies before consent has been sought TW
will obtain information from colleagues and establish the
most appropriate practitioner to notify parents of the re-
search involvement.
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Consent can be sought from parents following the
death of their child and prior to the parent’s departure
from the hospital. However, it is at the discretion of the
clinical staff to determine if this is appropriate for each
individual family. It maybe that it is not appropriate for
consent to be obtained prior to discharge [15, 16].
Following the death of a child at the RBHSC it is rou-
tine practice to invite the parents to a meeting with the
consultant in charge of their child’s care. This usually
takes place 4–6 week after death. At this meeting, the
consultant will be asked to explain the PiC study, rea-
sons for RWPC, how to opt in or out, and provide con-
tact details for the research team.
Following the meeting, 4 weeks is allowed for the fam-
ily to contact the research team. If no contact is made
then a personalised letter including the PIS and consent
form is sent to the family. This explains the study, rea-
sons for RWPC, how to opt in or out, and provides con-
tact details for the research team. If after 4 weeks after
sending the initial letter to the bereaved family, there is
no response, a follow up letter along with the parent
representative information sheet and consent form will
be sent to the bereaved family. This second letter will
explain the study, reasons for research without prior
consent (deferred consent), how to opt in or out of the
study and provide contact details if parents wish to dis-
cuss the study with a member of the research team (ei-
ther in person or by telephone). In addition, this letter
will also confirm that if no consent form is received
within 4 weeks of the letter being sent then the partici-
pant’s data will NOT be included in the study.
Deferred consent declined/not obtained
If RWPC is declined or not obtained the child’s data will
not be included. TW will maintain a record of all in-
stances of declined/not obtained consent.
Withdrawal of consent
Consent may be withdrawn at any time without provid-
ing a reason and without being subject to any resulting
detriment. The rights and welfare of the patients will be
protected and the quality of medical care will not be ad-
versely affected if they decline to participate in the study.
TW will maintain a record of all those that withdraw
consent to participate in the study.
Research Ethics Committee (REC) and Institutional
Review Board (IRB) opinion
The Northern Ireland REC and the Belfast Trust IRB
have both reviewed the PiC protocol and provided a
favorable outcome including the use of research
without prior consent (deferred consent) as described
above (Project ID 224660).
Statistical analysis
In keeping with the objectives we will report:
Primary:
1) The diagnostic accuracy of POCT for (i) N.
meningitidis DNA and (ii) PCT in the diagnosis of
early MD against the reference standard (qPCR) for
N. meningitidis DNA in blood/CSF). The sensitivity,
specificity, NPV and PPV will be reported.
2) The diagnostic accuracy of POCT for PCT in the
diagnosis of early invasive bacterial infection against
the reference standard of positive culture from a
sterile site (blood/CSF). The sensitivity, specificity,
NPV and PPV will be reported.
Secondary:
1) The diagnostic accuracy of existing UK guidance in
the diagnosis of early MD against the reference
standard qPCR) of blood/CSF. The sensitivity,
specificity, NPV and PPV will be reported.
McNemar’s test will be performed to determine the
significance in performance of different guidance.
Where possible the effect of incorporating POCT
into existing guidance will be explored and reported
in term of sensitivity, specificity, NPV and PPV.
2) Report on the aetiology of NBRs in children with a
feverish illness
3) The epidemiology of the population of children
who present with fever and a NBR
Qualitative analysis
Qualitative interview data will be transcribed verbatim,
checked and anonymised as the study progresses. QSR
NVivo software will be used to assist in the organization
and indexing of qualitative data. Data will be analyzed the-
matically, informed by the constant comparison approach
of grounded theory [18]. The focus will be modified to fit
with the criterion of catalytic validity, whereby findings
should be relevant to future research and practice.
Cost analysis
The PiC study will include a review of the economic im-
pact of the current management of children with fever
and a non-blanching rash and to assess the possible cost
analysis of the rapid POCT diagnostic tests compared to
standard care from the NHS perspective. Resource use for
PCT, LAMP-MD POCT and current standard tests will be
collected along with unit costs to identify mean costs in
delivering these tests. Resource use will be derived at the
individual patient level. Clinical staff will record the time
and activities undertaken for specimen collection. Associ-
ated costs will be calculated using a standard micro cost-
ing (bottom-up) approach, and will be based on clinical
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staff salaries plus on-costs (employer’s national insurance
and superannuation contributions) and appropriate cap-
ital, administration, laboratory and training costs. These
data will also inform the costs of designing and running a
large multicentre study.
Discussion
The PiC study represents a pragmatic approach to a dif-
ficult but important research question. PiC aims to de-
termine (i) the value of novel POCT strategies, (ii) the
performance of existing guidance, (iii) the role of both
these elements in the derivation of a CDR to aid clini-
cians in this area of diagnostic dilemma, and (iv) the
feasibility of deriving and validating such a CDR. We will
also provide important aetiological and epidemiological
data on childhood NBRs in the post-vaccine era.
Potential risks
Clinical risks are minimal as the PiC study doesn’t in-
volve any change to routine care. All children will still
be managed according to the existing meningococcal
treatment pathway in operation at the RBHSC. The re-
sults of the POCT will not be used to remove a child
from the care pathway. No additional blood samples or
throat swabs are required, as we use samples taken as
part of standard care.
Potential benefits
For children admitted to hospital for IV antibiotics, there
is no likelihood of personal benefit from participating in
this study. However for enrolled children who would
otherwise be discharged directly from the ED there is
potential benefit, as the results of the LAMP-MD and
PCT will be made available to the clinical team. Being
enrolled in this study may therefore result in the child
receiving lifesaving treatment that they would have
otherwise not received, with guidance provided for clini-
cians on meaningful test cut-points. [10, 12].
Potential bias
As the clinical team are not blinded to the results of the
index tests, there is an increased risk of bias in treatment.
It was deemed ethically unacceptable to withhold these re-
sults from clinicians. However as our performance accur-
acy is primarily assessed laboratory tests we expect any
bias to be minimized, with a residual risk remaining for
cases which require a clinical decision as to the likelihood
of MD in the context of negative laboratory tests. When
this occurs bias will be minimized by ensuring the treating
clinician is not part of this panel, with information taken
solely from clinical notes. In addition the laboratory team
performing reference tests will be blinded to index tests.
This includes blood culture testing and qPCR for other in-
vasive bacterial infections.
Limitations of the study
Whilst the PiC study is powered to provide useful data
on the diagnostic accuracy of POCT for PCT and N.
meningitidis DNA and to report on the performance of
existing guidance it is underpowered to define a new
clinical decision rule outright.
The learning from PiC s likely to inform the design of a
larger multicentre study and may also point towards areas
for further guideline/clinical decision rule development.
Study committees
Public & Patient Involvement Advisory Group (PPI)
The hope is that the PPI advisory group would play a
full part in all aspects of the study. In particular there is
a clear benefit of their involvement in the application for
ethical approval and with developing resources for par-
ents and children including the final publication of re-
sults and the development of patient information.
The chairperson of the PPI advisory group will be in-
volved with publication writing and will be named as a
co-author on the study and study protocol and all mem-
bers of the PPI advisory group would be encouraged to
attend the free HSCNI “Building Research Partnerships”
course. Additional funding will be made available to pro-
vide training for members of the PPI advisory group so
that they can confidently contribute to the study.
Independent study monitoring group
An independent study monitoring group chaired will
oversee the quality of the research and manage any po-
tential conflicts of interest.
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